STOCK TITAN

Omega Therapeutics Inc - OMGA STOCK NEWS

Welcome to our dedicated news page for Omega Therapeutics (Ticker: OMGA), a resource for investors and traders seeking the latest updates and insights on Omega Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Omega Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Omega Therapeutics's position in the market.

Rhea-AI Summary
Omega Therapeutics, Inc. presents new preclinical data on the anti-tumor effect of MYC-directed epigenomic controller in EGFR inhibitor-resistant NSCLC and validation of a novel translational assay for target engagement of OTX-2002 at AACR Annual Meeting 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
-
Rhea-AI Summary
Omega Therapeutics, Inc. (OMGA) announced encouraging initial clinical data for OTX-2002 in late-stage HCC patients. They also established a research collaboration with Novo Nordisk for obesity treatment, and prioritized resources to enhance shareholder value. Financially, as of December 31, 2023, Omega had $73.4 million in cash and marketable securities, expected to fund operations into Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
-
Rhea-AI Summary
Omega Therapeutics, Inc. (OMGA) will present two posters at the AACR Annual Meeting 2024, featuring preclinical data on epigenomic controller target engagement and MYC-targeting approach in NSCLC. The company aims to pioneer programmable epigenomic mRNA medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.47%
Tags
none
Rhea-AI Summary
Omega Therapeutics, Inc. (OMGA) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
conferences
-
Rhea-AI Summary
Omega Therapeutics, Inc. (Nasdaq: OMGA) will participate in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on December 6, 2023, at 9:30 a.m. ET. A live webcast will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
conferences
-
Rhea-AI Summary
Omega Therapeutics, Inc. (OMGA) to participate in fireside chat at Piper Sandler 35th Annual Healthcare Conference. The event will be live webcasted and available for replay on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
conferences
Rhea-AI Summary
Omega Therapeutics, Inc. (Nasdaq: OMGA) presented new preclinical data at The Liver Meeting® 2023, demonstrating sustained upregulation of gene expression and coordinated pre-transcriptional downregulation of multiple genes in models of liver fibrosis and inflammation. The data revealed the ability of an epigenomic controller to regulate the expression of chemokines CXCL9-11, offering groundbreaking insights into the development of programmable epigenomic mRNA medicines for liver diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
-
Rhea-AI Summary
Omega Therapeutics, Inc. (Nasdaq: OMGA) announced promising preliminary clinical data for OTX-2002 from ongoing MYCHELANGELO™ I trial, establishing clinical proof-of-platform. The data showed rapid, robust, and durable downregulation of MYC expression in patients with hepatocellular carcinoma and other solid tumors. The company also presented new preclinical data on multiple epigenomic controller programs and strengthened the Board of Directors. Financial results for the third quarter ended September 30, 2023, were highlighted, with $89.3 million in cash, cash equivalents, and marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
-
Rhea-AI Summary
OMGA: Omega Therapeutics to Participate in Fireside Chat at Jefferies London Healthcare Conference on November 14, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
conferences
Rhea-AI Summary
Omega Therapeutics announces new preclinical data demonstrating the ability of their OMEGA platform to modulate the epigenetic profile of CXCL1-8 genes and inhibit immune cell recruitment in multiple models of inflammatory disease. The platform enables multiplexing for controlled epigenomic modulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.43%
Tags
Omega Therapeutics Inc

Nasdaq:OMGA

OMGA Rankings

OMGA Stock Data

147.54M
21.36M
1.97%
94.48%
7.32%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Cambridge

About OMGA

omega therapeutics™ is a preclinical stage genomic medicine enterprise transforming medicine and patient care through precision genomic control. the company’s platform is focused on selectively directing the human genome to treat and cure disease by precisely controlling genomic expression without changing nucleic acid sequences. we are developing precision therapeutics for a range of disease indications including rare genetic diseases, immunology, inflammation, metabolic diseases and oncology. # transformativemedicines #pioneeringmedicines